“Both VX-150 and VX-128 represent an innovative new approach to the treatment of pain, and we are encouraged to now have positive proof-of-concept data from two studies of VX-150 that demonstrate for ...
- VX-264 Phase 1/2 enrollment and dosing complete in Parts A and B: VX-264 was generally safe and well tolerated; efficacy data are not supportive of further clinical advancement - - Zimislecel ...
- Clinical proof-of-concept achieved based on positive data from the first two patients dosed at half the target dose of cells in Part A of Phase 1/2 study - - First patient achieved insulin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback